• FirefoxInstall the new Firefox »
  •  Dow Up1.49% Nasdaq Up1.15%

    Franklin Biotechnology Discovery R6 (FRBRX)

    200.26 Up 3.98(2.03%) Mar 30

    Profile as of Feb 27, 2015Get Profile for:
    Franklin Biotechnology Discovery R6
    Franklin Strategic SeriesOne Franklin ParkwaySan Mateo, CA 94403-1906
    Phone: 800-632-2301
    Fund Overview 
    Fund Family:Franklin Templeton Investments
    Net Assets:1.93B
    Year-to-Date Return:11.40%
    Morningstar Rating:4 stars
    Fund Inception Date:May 1, 2013
    Morningstar Style Box 
    [View Category Definition]
    View Top Health Funds
    About the Morningstar Style Box
    Management Information 
    Evan S. McCulloch
    Lead Manager since Sep 15, 1997
    Mr. McCulloch has been a portfolio manager of the Fund since 1997 and assumed duties of lead portfolio manager of the Fund in 2000. He has primary responsibility for the investments of the Fund. He has final authority over all aspects of the Fund's investment portfolio, including but not limited to, purchases and sales of individual securities, portfolio risk assessment, and the management of daily cash balances in accordance with anticipated cash management requirements. The degree to which he may perform these functions, and the nature of these functions, may change from time to time.
    Investment Information 
    Min Initial Investment:1,000,000
    Min Initial Investment, IRA:N/A
    Min Initial Investment, AIP:N/A
    Min Subsequent Investment:N/A
    Min Subsequent Investment, IRA:N/A
    Min Subsequent Investment, AIP:N/A
    FRBRX can be purchased from 8 brokerages.

    Fund Summary 
    The investment seeks capital appreciation. Under normal market conditions, the fund invests at least 80% of its net assets in securities of biotechnology companies and discovery research firms. It predominantly invests in equity securities, primarily common stock. In addition to its investments in biotechnology companies, the fund may also invest up to 20% of its net assets in equity or debt securities of any type of foreign or U.S. issuer. It is non-diversified.

    Fund Operations 
    Last Dividend : 0.00
    Last Cap Gain (Dec 14, 2014) : 0.00
    Annual Holdings Turnover (Mar 26, 2015) : 48.70%
    Average for Category:55.28%
    Fees & Expenses 
    ExpenseFRBRXCategory Avg
    Annual Report Expense Ratio (net):0.63%1.43%
    Prospectus Net Expense Ratio:0.63%N/A
    Prospectus Gross Expense Ratio:0.63%N/A
    Max 12b1 Fee:N/AN/A
    Max Front End Sales Load:N/A5.28%
    Max Deferred Sales Load: N/A2.37%
    3 Yr Expense Projection*:202604
    5 Yr Expense Projection*:351926
    10 Yr Expense Projection*:7861,819
    * Per $10,000 invested